LEXICON PHARMACEUTICALS, INC. Research and Development Expense
LEXICON PHARMACEUTICALS, INC. (LXRX) reported Research and Development Expense of $17.44 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- LEXICON PHARMACEUTICALS, INC. research and development expense for the quarter ending 2026-06-30 was $17.44M, a 10.77% increase year-over-year.
- LEXICON PHARMACEUTICALS, INC. research and development expense for the quarter ending 2026-03-31 was $12.76M, a 16.64% decline year-over-year.
- LEXICON PHARMACEUTICALS, INC. research and development expense for the quarter ending 2025-12-31 was $11.31M, a 57.60% decline year-over-year.
- LEXICON PHARMACEUTICALS, INC. research and development expense for the quarter ending 2025-09-30 was $18.76M, a 27.24% decline year-over-year.
- LEXICON PHARMACEUTICALS, INC. research and development expense for fiscal 2025 was $61.12M, a 27.65% decline from fiscal 2024.
- LEXICON PHARMACEUTICALS, INC. research and development expense for fiscal 2024 was $84.48M, a 43.46% increase from fiscal 2023.
- LEXICON PHARMACEUTICALS, INC. research and development expense for fiscal 2023 was $58.89M, a 11.49% increase from fiscal 2022.
- LEXICON PHARMACEUTICALS, INC. research and development expense for fiscal 2022 was $52.82M, a 4.05% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $17.44M 10-Q · filed 2026-08-06 | $30.20M 10-Q · filed 2026-08-06 | $41.51M derived: sum of 3 quarters · filed 2026-08-06 | $60.27M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $12.76M 10-Q · filed 2026-05-07 | $24.07M derived: sum of 2 quarters · filed 2026-05-07 | $42.83M derived: sum of 3 quarters · filed 2026-05-07 | $58.58M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $11.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $30.07M derived: sum of 2 quarters · filed 2026-03-05 | $45.82M derived: sum of 3 quarters · filed 2026-08-06 | $61.12M 10-K · filed 2026-03-05 | ||||
| 2025-09-30 | $18.76M 10-Q · filed 2025-11-06 | $34.50M derived: sum of 2 quarters · filed 2026-08-06 | $49.81M 10-Q · filed 2025-11-06 | $76.49M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $15.75M 10-Q · filed 2026-08-06 | $31.05M 10-Q · filed 2026-08-06 | $57.73M derived: sum of 3 quarters · filed 2026-08-06 | $83.52M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $15.30M 10-Q · filed 2026-05-07 | $41.99M derived: sum of 2 quarters · filed 2026-05-07 | $67.77M derived: sum of 3 quarters · filed 2026-05-07 | $85.41M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | $26.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $52.47M derived: sum of 2 quarters · filed 2026-03-05 | $70.11M derived: sum of 3 quarters · filed 2026-03-05 | $84.48M 10-K · filed 2026-03-05 | ||||
| 2024-09-30 | $25.78M 10-Q · filed 2025-11-06 | $43.42M derived: sum of 2 quarters · filed 2025-11-06 | $57.80M 10-Q · filed 2025-11-06 | $72.56M derived: sum of 4 quarters · filed 2026-03-05 | ||||
| 2024-06-30 | $17.64M 10-Q · filed 2025-08-06 | $32.02M 10-Q · filed 2025-08-06 | $46.78M derived: sum of 3 quarters · filed 2026-03-05 | $64.33M derived: sum of 4 quarters · filed 2026-03-05 | ||||
| 2024-03-31 | $14.37M 10-Q · filed 2025-05-14 | $29.13M derived: sum of 2 quarters · filed 2026-03-05 | $46.69M derived: sum of 3 quarters · filed 2026-03-05 | $61.23M derived: sum of 4 quarters · filed 2026-03-05 | ||||
| 2023-12-31 | $14.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $32.32M derived: sum of 2 quarters · filed 2026-03-05 | $46.86M derived: sum of 3 quarters · filed 2026-03-05 | $58.89M 10-K · filed 2026-03-05 | ||||
| 2023-09-30 | $17.56M 10-Q · filed 2024-11-13 | $32.10M derived: sum of 2 quarters · filed 2024-11-13 | $44.13M 10-Q · filed 2024-11-13 | $58.10M derived: sum of 4 quarters · filed 2025-03-07 | ||||
| 2023-06-30 | $14.54M 10-Q · filed 2024-08-02 | $26.57M 10-Q · filed 2024-08-02 | $40.54M derived: sum of 3 quarters · filed 2025-03-07 | $51.10M derived: sum of 4 quarters · filed 2025-03-07 | ||||
| 2023-03-31 | $12.03M 10-Q · filed 2024-05-02 | $26.00M derived: sum of 2 quarters · filed 2025-03-07 | $36.56M derived: sum of 3 quarters · filed 2025-03-07 | $49.92M derived: sum of 4 quarters · filed 2025-03-07 | ||||
| 2022-12-31 | $13.98M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $24.53M derived: sum of 2 quarters · filed 2025-03-07 | $37.89M derived: sum of 3 quarters · filed 2025-03-07 | $52.82M 10-K · filed 2025-03-07 | ||||
| 2022-09-30 | $10.56M 10-Q · filed 2023-11-08 | $23.91M derived: sum of 2 quarters · filed 2023-11-08 | $38.84M 10-Q · filed 2023-11-08 | $55.34M derived: sum of 4 quarters · filed 2024-03-25 | ||||
| 2022-06-30 | $13.36M 10-Q · filed 2023-08-04 | $28.28M 10-Q · filed 2023-08-04 | $44.78M derived: sum of 3 quarters · filed 2024-03-25 | $60.46M derived: sum of 4 quarters · filed 2024-03-25 | ||||
| 2022-03-31 | $14.93M 10-Q · filed 2023-05-04 | $31.42M derived: sum of 2 quarters · filed 2024-03-25 | $47.11M derived: sum of 3 quarters · filed 2024-03-25 | $57.36M derived: sum of 4 quarters · filed 2024-03-25 | ||||
| 2021-12-31 | $16.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $32.18M derived: sum of 2 quarters · filed 2024-03-25 | $42.44M derived: sum of 3 quarters · filed 2024-03-25 | $55.05M 10-K · filed 2024-03-25 | ||||
| 2021-09-30 | $15.68M 10-Q · filed 2022-11-09 | $25.94M derived: sum of 2 quarters · filed 2022-11-09 | $38.55M 10-Q · filed 2022-11-09 | $39.54M derived: sum of 4 quarters · filed 2023-03-03 | ||||
| 2021-06-30 | $10.26M 10-Q · filed 2022-08-03 | $22.87M 10-Q · filed 2022-08-03 | $23.86M derived: sum of 3 quarters · filed 2023-03-03 | $64.00M derived: sum of 4 quarters · filed 2023-03-03 | ||||
| 2021-03-31 | $12.61M 10-Q · filed 2022-05-05 | $13.60M derived: sum of 2 quarters · filed 2023-03-03 | $53.75M derived: sum of 3 quarters · filed 2023-03-03 | $111.05M derived: sum of 4 quarters · filed 2023-03-03 | ||||
| 2020-12-31 | $992.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | $41.14M derived: sum of 2 quarters · filed 2023-03-03 | $98.44M derived: sum of 3 quarters · filed 2023-03-03 | $153.62M 10-K · filed 2023-03-03 | ||||
| 2020-09-30 | $40.15M 10-Q · filed 2021-11-09 | $97.45M derived: sum of 2 quarters · filed 2021-11-09 | $152.63M 10-Q · filed 2021-11-09 | $193.24M derived: sum of 4 quarters · filed 2022-03-10 | ||||
| 2020-06-30 | $57.30M 10-Q · filed 2021-08-06 | $112.48M 10-Q · filed 2021-08-06 | $153.09M derived: sum of 3 quarters · filed 2022-03-10 | $179.75M derived: sum of 4 quarters · filed 2022-03-10 | ||||
| 2020-03-31 | $55.18M 10-Q · filed 2021-05-06 | $95.79M derived: sum of 2 quarters · filed 2022-03-10 | $122.45M derived: sum of 3 quarters · filed 2022-03-10 | $135.08M derived: sum of 4 quarters · filed 2022-03-10 | ||||
| 2019-12-31 | $40.61M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $67.27M derived: sum of 2 quarters · filed 2022-03-10 | $79.90M derived: sum of 3 quarters · filed 2022-03-10 | $91.92M 10-K · filed 2022-03-10 | ||||
| 2019-09-30 | $26.66M 10-Q · filed 2020-10-30 | $39.30M derived: sum of 2 quarters · filed 2020-10-30 | $51.32M 10-Q · filed 2020-10-30 | $63.63M derived: sum of 4 quarters · filed 2021-03-12 | ||||
| 2019-06-30 | $12.64M 10-Q · filed 2020-07-29 | $24.66M 10-Q · filed 2020-07-29 | $36.97M derived: sum of 3 quarters · filed 2021-03-12 | $50.73M derived: sum of 4 quarters · filed 2021-03-12 | ||||
| 2019-03-31 | $12.02M 10-Q · filed 2020-04-27 | $24.33M derived: sum of 2 quarters · filed 2021-03-12 | $38.09M derived: sum of 3 quarters · filed 2021-03-12 | $64.57M derived: sum of 4 quarters · filed 2021-03-12 | ||||
| 2018-12-31 | $12.31M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $26.07M derived: sum of 2 quarters · filed 2021-03-12 | $52.55M derived: sum of 3 quarters · filed 2021-03-12 | $100.24M 10-K · filed 2021-03-12 | ||||
| 2018-09-30 | $13.76M 10-Q · filed 2019-11-07 | $13.77M 10-Q · filed 2018-11-01 | $40.24M derived: sum of 2 quarters · filed 2019-11-07 | $87.94M 10-Q · filed 2019-11-07 | $88.14M 10-Q · filed 2018-11-01 | $130.51M derived: sum of 4 quarters · filed 2020-03-12 | ||
| 2018-06-30 | $26.48M 10-Q · filed 2019-08-01 | $26.59M 10-Q · filed 2018-07-30 | $74.17M 10-Q · filed 2019-08-01 | $74.37M 10-Q · filed 2018-07-30 | $116.74M derived: sum of 3 quarters · filed 2020-03-12 | $155.88M derived: sum of 4 quarters · filed 2020-03-12 | ||
| 2018-03-31 | $47.70M 10-Q · filed 2019-05-01 | $47.78M 10-Q · filed 2018-05-03 | $90.27M derived: sum of 2 quarters · filed 2020-03-12 | $129.40M derived: sum of 3 quarters · filed 2020-03-12 | $156.34M derived: sum of 4 quarters · filed 2020-03-12 | |||
| 2017-12-31 | $42.57M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $81.71M derived: sum of 2 quarters · filed 2020-03-12 | $108.64M derived: sum of 3 quarters · filed 2020-03-12 | $152.22M 10-K · filed 2020-03-12 | $156.81M 10-K · filed 2018-03-01 | |||
| 2017-09-30 | $39.14M 10-Q · filed 2018-11-01 | $66.07M derived: sum of 2 quarters · filed 2018-11-01 | $109.65M 10-Q · filed 2018-11-01 | $135.87M derived: sum of 4 quarters · filed 2019-03-15 | ||||
| 2017-06-30 | $26.93M 10-Q · filed 2018-07-30 | $70.52M 10-Q · filed 2018-07-30 | $96.74M derived: sum of 3 quarters · filed 2019-03-15 | $149.27M derived: sum of 4 quarters · filed 2019-03-15 | ||||
| 2017-03-31 | $43.58M 10-Q · filed 2018-05-03 | $69.80M derived: sum of 2 quarters · filed 2019-03-15 | $122.34M derived: sum of 3 quarters · filed 2019-03-15 | $170.55M derived: sum of 4 quarters · filed 2019-03-15 | ||||
| 2016-12-31 | $26.22M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-15 | $78.75M derived: sum of 2 quarters · filed 2019-03-15 | $126.97M derived: sum of 3 quarters · filed 2019-03-15 | $163.97M 10-K · filed 2019-03-15 | $178.15M 10-K · filed 2017-03-06 | |||
| 2016-09-30 | $52.53M 10-Q · filed 2017-11-08 | $100.75M derived: sum of 2 quarters · filed 2017-11-08 | $137.75M 10-Q · filed 2017-11-08 | $168.19M derived: sum of 4 quarters · filed 2018-03-01 | ||||
| 2016-06-30 | $48.22M 10-Q · filed 2017-08-01 | $85.22M 10-Q · filed 2017-08-01 | $115.66M derived: sum of 3 quarters · filed 2018-03-01 | $138.77M derived: sum of 4 quarters · filed 2018-03-01 | ||||
| 2016-03-31 | $37.00M 10-Q · filed 2017-05-04 | $67.44M derived: sum of 2 quarters · filed 2018-03-01 | $90.56M derived: sum of 3 quarters · filed 2018-03-01 | $111.32M derived: sum of 4 quarters · filed 2018-03-01 | ||||
| 2015-12-31 | $30.44M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $53.55M derived: sum of 2 quarters · filed 2018-03-01 | $74.32M derived: sum of 3 quarters · filed 2018-03-01 | $95.19M 10-K · filed 2018-03-01 | ||||
| 2015-09-30 | $23.11M 10-Q · filed 2016-11-07 | $43.88M derived: sum of 2 quarters · filed 2016-11-07 | $64.75M 10-Q · filed 2016-11-07 | $84.78M derived: sum of 4 quarters · filed 2017-03-06 | ||||
| 2015-06-30 | $20.77M 10-Q · filed 2016-08-04 | $41.63M 10-Q · filed 2016-08-04 | $61.66M derived: sum of 3 quarters · filed 2017-03-06 | $85.77M derived: sum of 4 quarters · filed 2017-03-06 | ||||
| 2015-03-31 | $20.86M 10-Q · filed 2016-05-05 | $40.90M derived: sum of 2 quarters · filed 2017-03-06 | $65.00M derived: sum of 3 quarters · filed 2017-03-06 | $86.19M derived: sum of 4 quarters · filed 2017-03-06 | ||||
| 2014-12-31 | $20.03M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-06 | $44.14M derived: sum of 2 quarters · filed 2017-03-06 | $65.33M derived: sum of 3 quarters · filed 2017-03-06 | $89.28M 10-K · filed 2017-03-06 | ||||
| 2014-09-30 | $24.11M 10-Q · filed 2015-11-09 | $45.30M derived: sum of 2 quarters · filed 2015-11-09 | $69.25M 10-Q · filed 2015-11-09 | $89.51M derived: sum of 4 quarters · filed 2016-03-11 | ||||
| 2014-06-30 | $21.19M 10-Q · filed 2015-08-07 | $45.14M 10-Q · filed 2015-08-07 | $65.40M derived: sum of 3 quarters · filed 2016-03-11 | $90.80M derived: sum of 4 quarters · filed 2016-03-11 | ||||
| 2014-03-31 | $23.95M 10-Q · filed 2015-05-05 | $44.22M derived: sum of 2 quarters · filed 2016-03-11 | $69.62M derived: sum of 3 quarters · filed 2016-03-11 | $93.31M derived: sum of 4 quarters · filed 2016-03-11 | ||||
| 2013-12-31 | $20.26M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-11 | $45.66M derived: sum of 2 quarters · filed 2016-03-11 | $69.36M derived: sum of 3 quarters · filed 2016-03-11 | $89.68M 10-K · filed 2016-03-11 | ||||
| 2013-09-30 | $25.40M 10-Q · filed 2014-11-06 | $49.09M derived: sum of 2 quarters · filed 2014-11-06 | $69.42M 10-Q · filed 2014-11-06 | $90.41M derived: sum of 4 quarters · filed 2015-03-12 | ||||
| 2013-06-30 | $23.69M 10-Q · filed 2014-08-07 | $44.02M 10-Q · filed 2014-08-07 | $65.01M derived: sum of 3 quarters · filed 2015-03-12 | $84.20M derived: sum of 4 quarters · filed 2015-03-12 | ||||
| 2013-03-31 | $20.33M 10-Q · filed 2014-05-08 | $41.32M derived: sum of 2 quarters · filed 2015-03-12 | $60.51M derived: sum of 3 quarters · filed 2015-03-12 | $79.86M derived: sum of 4 quarters · filed 2015-03-12 | ||||
| 2012-12-31 | $20.99M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | $40.18M derived: sum of 2 quarters · filed 2015-03-12 | $59.54M derived: sum of 3 quarters · filed 2015-03-12 | $82.57M 10-K · filed 2015-03-12 | ||||
| 2012-09-30 | $19.19M 10-Q · filed 2013-11-12 | $38.55M derived: sum of 2 quarters · filed 2013-11-12 | $61.58M 10-Q · filed 2013-11-12 | $89.69M derived: sum of 4 quarters · filed 2014-03-07 | ||||
| 2012-06-30 | $19.36M 10-Q · filed 2013-08-01 | $42.39M 10-Q · filed 2013-08-01 | $70.50M derived: sum of 3 quarters · filed 2014-03-07 | $90.15M derived: sum of 4 quarters · filed 2014-03-07 | ||||
| 2012-03-31 | $23.04M 10-Q · filed 2013-05-10 | $51.14M derived: sum of 2 quarters · filed 2014-03-07 | $70.80M derived: sum of 3 quarters · filed 2014-03-07 | $90.94M derived: sum of 4 quarters · filed 2014-03-07 | ||||
| 2011-12-31 | $28.11M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-07 | $47.76M derived: sum of 2 quarters · filed 2014-03-07 | $67.91M derived: sum of 3 quarters · filed 2014-03-07 | $91.83M 10-K · filed 2014-03-07 | ||||
| 2011-09-30 | $19.66M 10-Q · filed 2012-11-07 | $39.80M derived: sum of 2 quarters · filed 2012-11-07 | $63.72M 10-Q · filed 2012-11-07 | $81.97M derived: sum of 4 quarters · filed 2013-03-11 | ||||
| 2011-06-30 | $20.14M 10-Q · filed 2012-08-02 | $44.07M 10-Q · filed 2012-08-02 | $62.32M derived: sum of 3 quarters · filed 2013-03-11 | $81.26M derived: sum of 4 quarters · filed 2013-03-11 | ||||
| 2011-03-31 | $23.92M 10-Q · filed 2012-05-03 | $42.17M derived: sum of 2 quarters · filed 2013-03-11 | $61.11M derived: sum of 3 quarters · filed 2013-03-11 | $81.35M derived: sum of 4 quarters · filed 2013-03-11 | ||||
| 2010-12-31 | $18.25M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-11 | $37.19M derived: sum of 2 quarters · filed 2013-03-11 | $57.43M derived: sum of 3 quarters · filed 2013-03-11 | $78.52M 10-K · filed 2013-03-11 | ||||
| 2010-09-30 | $18.94M 10-Q · filed 2011-11-01 | $39.18M derived: sum of 2 quarters · filed 2011-11-01 | $60.27M 10-Q · filed 2011-11-01 | |||||
| 2010-06-30 | $20.24M 10-Q · filed 2011-08-09 | $41.33M 10-Q · filed 2011-08-09 | ||||||
| 2009-12-31 | $81.24M 10-K · filed 2012-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |